BioCentury
ARTICLE | Clinical News

CPC-201: Phase II data

September 5, 2016 7:00 AM UTC

A single-blind, dose-escalation, crossover, U.S. Phase II trial in 33 evaluable patients with AD type dementia who were being successfully treated with 10 mg/day donepezil showed that CPC-201 met the ...